The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.
London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.
LGC will offer NuGen's single-primer enrichment technology for next-generation sequencing target enrichment.
LGC will supply DNA fragmentation instruments for clinical and agricultural biotechnology customers.
The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.
Backed by €15 million in EU funding, the Ubiquitous Pharmacogenomics Consortium seeks to implement preemptive testing at seven healthcare systems by 2020.
The partners will evaluate several quality control assays for genome editing research, eventually creating a protocol for analyzing mutations in genomic DNA.
The UK-based firm plans to marry its core strengths with the probes and PCR platforms, and to build its sales force in the US.
LGC said it plans to use Douglas Scientific's PCR and qPCR platforms to provide customers with enhanced high-throughput genotyping and qPCR instruments.
The two companies will use KeyGene's technology for the genetic analysis of field and vegetable crops.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.